<?xml version="1.0"?>

<document>
	<title>Long-term tobramycin therapy in patients with cystic fibrosis and
   advanced pulmonary disease.</title>

	<author>Paporisz-U.</author>
	<author>Posselt-H-G.</author>
	<author>Wonne-R.</author>
	<author>Ristow-W.</author>
	<author>Roser-D.</author>
	<author>Knothe-H.</author>
	<author>Bender-S-W.</author>

	<source>Monogr-Paediatr. 1979. 10. P 31-3.</source>

	<abstract>The aim of our clinical study was to find if prolonged tobramycin
   therapy can prevent further rapid deterioration in cystic fibrosis
   patients.  Eleven courses of treatment were given to the nine
   patients.  Eight of these markedly improved their physical activity
   and gained weight.  However, only in four of these patients was
   clinical improvement correlated with an improved radiogram.
   Pseudomonas was eradicated from the sputum of only four patients
   during therapy but reappeared in three of them before the end of
   therapy.  Clinical improvement and negligible side effects suggest
   treatment of exacerbating Pyocyaneus bronchopneumonia with prolonged
   tobramycin therapy.  Dosage should be higher than 5 mg/kg/day with
   strict control of tobramycin blood level and awareness of side
   effects.</abstract>

	<majorsubject>ANTIBIOTICS: ad</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: dt</majorsubject>
	<majorsubject>LUNG-DISEASES: dt</majorsubject>
	<majorsubject>TOBRAMYCIN: ad</majorsubject>

	<minorsubject>CYSTIC-FIBROSIS: co</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>INFANT</minorsubject>
	<minorsubject>LUNG-DISEASES: et</minorsubject>
	<minorsubject>PSEUDOMONAS-INFECTIONS: dt, et</minorsubject>
	<minorsubject>TIME-FACTORS</minorsubject>
	<minorsubject>TOBRAMYCIN: tu</minorsubject>

	<reference>001   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971</reference>
	<reference>002   DOGGETT RG            SOUTH MED J                     61  1347 968</reference>
	<reference>003   DOGGETT RG            J BACTERIOL                     87   427 964</reference>
	<reference>004   DOGGETT RG            SOUTH MED J                     57  1476 964</reference>
	<reference>005   DOGGETT RG            SOUTH MED J                     57  1470 964</reference>
	<reference>006   DOGGETT RG            SOUTH MED J                     61  1346 968</reference>
	<reference>007   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969</reference>
	<reference>008   DOGGETT RG            BACT PROC                       69    87 969</reference>
	<reference>009   DOGGETT RG            INFECT IMMUN                     6   628 972</reference>
	<reference>010   HAWLEY HB             CURR THER RES                   16   414 974</reference>
	<reference>011   HARRISON GM           PAEDIATRICIAN                    1   180 972</reference>
	<reference>012   HOFF GE               SCAND J INFECT DIS               6   333 974</reference>
	<reference>013   HOIBY N               SCAND J RESPIR DIS              58    65 977</reference>
	<reference>014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974</reference>
	<reference>015   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            968</reference>
	<reference>016   MEARNS MB             ARCH DIS CHILD                  47   902 972</reference>
	<reference>017   WAITZ JA              ANTIMICROB AGENTS CHEMOTHER      2   431 972</reference>
	<reference>018   HUMPHREY JH           ADV IMMUNOL                     11    75 969</reference>


</document>
